Pfizer secures up to $1.5B to test a monthly GLP-1 shot
Blackstone will fund up to $1.5B for Pfizer’s experimental monthly GLP-1 drug as larger trials test whether fewer injections can sustain weight loss.

Blackstone Life Sciences has agreed to cover up to $1.5 billion in development costs through 2028 for Pfizer’s experimental obesity drug berobenatide. Pfizer announced the agreement on November 11 as it advances a GLP-1 treatment designed for monthly maintenance dosing.
The goal, covered in The Rundown’s November 13 issue, is to sustain weight loss with fewer injections. Pfizer has reported encouraging results from patients who switched from weekly to monthly shots. Larger trials will test whether that promise holds.
What the funding covers
Pfizer describes 10 ongoing or planned Phase 3 trials covering weight management and conditions linked to obesity, including obstructive sleep apnea and knee osteoarthritis. The company will retain operational control of the drug.
Blackstone could receive milestone payments tied to U.S. approval of berobenatide as a monthly treatment on its own for chronic weight management and to specified sales targets.
What the trial showed
In Phase 2b results released on February 3, Pfizer described the VESPER-3 trial, in which participants received weekly injections through week 12 and then monthly injections through week 28. Patients continued losing weight after the switch, according to Pfizer.
Pfizer’s efficacy analysis showed up to 12.3% average weight loss at week 28 after adjusting for placebo. That result covers both dosing periods. All four tested regimens beat placebo on the trial’s main weight reduction measure.
Why it matters
Novo Nordisk’s daily Saxenda won U.S. approval in December 2014. Weekly Wegovy followed in June 2021. In less than seven years, GLP-1 drugs approved for obesity in the U.S. went from daily to weekly dosing. Pfizer could extend that progression if monthly treatment delivers lasting results.
Under the schedule Pfizer presented in June, monthly maintenance means an injection every four weeks. Over 52 weeks, that works out to about 13 injections, compared with 52 on a weekly schedule. That reduction begins after the initial weekly dosing phase.
For patients managing obesity over time, fewer injections could make treatment less demanding. Whether that helps people stay on the medicine longer remains unproven.
Pfizer’s June presentation projects weight loss similar to tirzepatide, the drug in Lilly’s Zepbound, at 72 weeks. That estimate comes from a statistical model drawing on results across studies. Pfizer cautions that actual trial results may differ, so the forecast leaves the efficacy comparison open.
Pfizer also reported that 9.3% of berobenatide participants in VESPER-3 stopped treatment because of health problems that arose during treatment. Larger studies must establish the balance between lasting weight loss and the risk of side effects. For patients and doctors, the appeal of monthly dosing depends on whether patients can keep taking the medicine.
Blackstone’s payment terms make approval of a monthly treatment a specific commercial goal. If Phase 3 confirms sustained weight loss with side effects patients can tolerate, convenience could become another basis for competition with Lilly and Novo Nordisk.
Sources & further reading
- 01therundown.ai ↗
- 02Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program | Pfizer ↗
- 03Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial | Pfizer ↗
- 04PowerPoint Presentation ↗
- 05News Details ↗
- 06News Details ↗
This story builds on reporting from The Rundown newsletter on November 13, 2026.